Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial

Patients with bipolar disorder (BD) do not always achieve full remission between episodes. Subthreshold symptoms (depressive, manic or mixed) represent a major cause of relapse and disability in these patients. Immediate release (IR) and extended release (XR) formulations of quetiapine are both indicated for short and long-term treatment of BD. The aim of this study was to evaluate the efficacy of quetiapine XR vs placebo in subthreshold symptomatology when added to previous mood stabilizer treatment.

Source: European Neuropsychopharmacology - September 4, 2017 Category: Psychiatry & Psychology Authors: Marina Garriga, Eva Sol é, Ana González-Pinto, Gabriel Selva-Vera, Belén Arranz, Benedikt L. Amann, Jerónimo Saiz-Ruiz, Josefina Pérez-Blanco, Eduard Vieta Source Type: research